Accellent grows revenue but losses widen

Accellent sprouted healthy revenue growth in its 2013 second quarter, but reorganization costs helped push net losses higher for the medical device contract manufacturer.

The Wilmington, MA, company booked $130.7 million in net sales during the quarter, up 3.8% from $126 million over the same period in 2012. Net losses hit $12.7 million, more than double the $5.6 million net loss in the 2012 second quarter. That stems in part from a $12.1 million pretax goodwill impairment charge arising from the company's reorganization into two segments, cardio & vascular and advanced surgical.

Company President and CEO Donald Spence said in a statement that the company's reorganization is working and set to create long-term benefits for the company.

"Our reorganization into two segments continues to align our strategy with our customers' needs," Spence said. "I am optimistic that our actions will continue to generate positive results."

Broken down, the company generated $80.7 million in net sales in its cardio and vascular business, a 2.2% rise over the previous year. Advanced surgical sales reached $50 million during the quarter, a 6.4% hike compared to Q2 2012. 

Accellent focuses on cardiology, endoscopy and orthopedic-related medical device contract manufacturing.

- read the release

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.